Zonegran Capsule
Product Images NDC 59212-680

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Zonegran (NDC 59212-680). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanz Pharma (us) Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg

100mg
Store these capsules in a dry place at a temperature of 25°C (77°F) with excursions allowed between 15-30°C (59-86°F). Keep them protected from light. The usual dosage information cannot be provided, and it is advised to see the accompanying prescribing information. These capsules are distributed by Amdipharm Limited from Dublin, Ireland, manufactured in Japan. These capsules are labeled as Zonegran, contain 100mg dosage, and are sold in a package of 100 capsules (NDC 59212-680-10). A medication guide is included with the capsules, and each patient should be given their own. These capsules were made for Concordia Pharmaceuticals and include non-varnish lot/exp serialization areas.*
FDA Label Image

25mg

25mg
Store the Zonegran (zonisamide) capsules at room temperature between 15-30°C (59-86°F) in a dry and light-protected place. The usual dosage for the medication is not available. The medication should be accompanied by a prescribing information and medication guide provided to each patient. The capsules are distributed by Amdipharm Limited in Dublin, Ireland and produced in Japan. The medication is manufactured for Concordia Pharmaceuticals and has a lot/exp serial number area, however, further information is not available from the obtained text.*
FDA Label Image

Zonegran-01 (Zonegran 1)

FDA Label Image

Zonegran-02 (Zonegran 2)

Zonegran-02 (Zonegran 2)
The text is describing the percentage reduction in all partial seizures rate between the medication Zonegran and a placebo. No specific percentage is given, and the rest of the text is not available due to missing characters.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.